IL285201B2 - EZH2 inhibitors for the treatment of lymphoma - Google Patents

EZH2 inhibitors for the treatment of lymphoma

Info

Publication number
IL285201B2
IL285201B2 IL285201A IL28520121A IL285201B2 IL 285201 B2 IL285201 B2 IL 285201B2 IL 285201 A IL285201 A IL 285201A IL 28520121 A IL28520121 A IL 28520121A IL 285201 B2 IL285201 B2 IL 285201B2
Authority
IL
Israel
Prior art keywords
ezh2
subject
compound
tumor
cancer
Prior art date
Application number
IL285201A
Other languages
English (en)
Hebrew (he)
Other versions
IL285201B1 (en
IL285201A (en
Original Assignee
Epizyme Inc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Eisai R&D Man Co Ltd filed Critical Epizyme Inc
Publication of IL285201A publication Critical patent/IL285201A/en
Publication of IL285201B1 publication Critical patent/IL285201B1/en
Publication of IL285201B2 publication Critical patent/IL285201B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL285201A 2014-06-17 2015-06-17 EZH2 inhibitors for the treatment of lymphoma IL285201B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013522P 2014-06-17 2014-06-17
US201462036265P 2014-08-12 2014-08-12
PCT/US2015/036310 WO2015195848A1 (en) 2014-06-17 2015-06-17 Ezh2 inhibitors for treating lymphoma

Publications (3)

Publication Number Publication Date
IL285201A IL285201A (en) 2021-08-31
IL285201B1 IL285201B1 (en) 2024-01-01
IL285201B2 true IL285201B2 (en) 2024-05-01

Family

ID=54936086

Family Applications (3)

Application Number Title Priority Date Filing Date
IL285201A IL285201B2 (en) 2014-06-17 2015-06-17 EZH2 inhibitors for the treatment of lymphoma
IL309539A IL309539A (en) 2014-06-17 2015-06-17 Ezh2 inhibitors for treating lymphoma
IL249438A IL249438A0 (en) 2014-06-17 2016-12-07 ezh2 inhibitors for the treatment of lymphoma

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL309539A IL309539A (en) 2014-06-17 2015-06-17 Ezh2 inhibitors for treating lymphoma
IL249438A IL249438A0 (en) 2014-06-17 2016-12-07 ezh2 inhibitors for the treatment of lymphoma

Country Status (21)

Country Link
US (5) US10166238B2 (esLanguage)
EP (2) EP3157527B1 (esLanguage)
JP (1) JP6779793B2 (esLanguage)
KR (2) KR102497728B1 (esLanguage)
CN (2) CN113289022A (esLanguage)
AU (3) AU2015277139A1 (esLanguage)
BR (1) BR112016029492A2 (esLanguage)
CA (1) CA2952074C (esLanguage)
DK (1) DK3157527T3 (esLanguage)
EA (1) EA038337B1 (esLanguage)
ES (1) ES2948442T3 (esLanguage)
FI (1) FI3157527T3 (esLanguage)
HU (1) HUE062158T2 (esLanguage)
IL (3) IL285201B2 (esLanguage)
LT (1) LT3157527T (esLanguage)
MX (2) MX383866B (esLanguage)
PL (1) PL3157527T3 (esLanguage)
PT (1) PT3157527T (esLanguage)
SG (2) SG10201811128RA (esLanguage)
SI (1) SI3157527T1 (esLanguage)
WO (1) WO2015195848A1 (esLanguage)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
MX376008B (es) 2012-10-15 2025-03-07 Epizyme Inc Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX373187B (es) 2013-12-06 2020-04-13 Epizyme Inc Terapia de combinación para tratar cáncer.
MX383866B (es) * 2014-06-17 2025-03-14 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
CN106794177A (zh) 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
FI3220916T3 (fi) 2014-11-17 2023-06-19 Epizyme Inc Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2016172199A1 (en) 2015-04-20 2016-10-27 Epizyme, Inc. Combination therapy for treating cancer
WO2016201328A1 (en) * 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
IL307260A (en) 2015-08-24 2023-11-01 Epizyme Inc Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
JP2019503391A (ja) * 2016-01-29 2019-02-07 エピザイム，インコーポレイティド 癌を処置するための併用療法
EP3464643A4 (en) 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
US11147819B2 (en) * 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
CN110475557B (zh) * 2017-01-20 2023-06-20 星座制药公司 固体分散体
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. USE OF EZH2 INHIBITORS TO TREAT CANCER
WO2019014191A1 (en) * 2017-07-10 2019-01-17 Constellation Pharmaceuticals, Inc. GENE EXPRESSION INDUCED BY EZH2 INHIBITOR
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
US20220298222A1 (en) * 2019-08-22 2022-09-22 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价
AU2021280314A1 (en) * 2020-05-28 2022-12-08 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062720A2 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
KR102511807B1 (ko) 2010-09-10 2023-03-20 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2760452A4 (en) 2011-09-30 2015-04-01 Glaxosmithkline Llc METHOD FOR TREATING CARCINOMA
KR102267502B1 (ko) * 2012-03-12 2021-06-24 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
RU2699546C2 (ru) 2012-04-13 2019-09-06 Эпизайм, Инк. Комбинированная терапия для лечения рака
DK3628670T3 (da) 2012-04-13 2022-12-05 Epizyme Inc Saltform til ezh2-hæmning
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
KR102057366B1 (ko) 2012-10-15 2019-12-18 에피자임, 인코포레이티드 치환된 벤젠 화합물
US20150283142A1 (en) 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
MX386085B (es) * 2012-11-01 2025-03-18 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
AU2013361060B2 (en) 2012-12-21 2018-04-19 Epizyme, Inc. 1,4-pyridone compounds
AU2013361079B2 (en) 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
CN105593378B (zh) 2013-10-09 2019-09-20 豪夫迈·罗氏有限公司 用于在人ezh2基因中检测突变的方法和组合物
ES2960953T3 (es) 2013-10-16 2024-03-07 Epizyme Inc Forma de sal de clorhidrato para la inhibición de EZH2
EP3057594A4 (en) 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
MX373187B (es) 2013-12-06 2020-04-13 Epizyme Inc Terapia de combinación para tratar cáncer.
MX383866B (es) 2014-06-17 2025-03-14 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
KR20170098808A (ko) 2014-11-06 2017-08-30 다나-파버 캔서 인스티튜트 인크. 이식편 대 숙주 질환 (gvhd)에 대한 염색질 구조를 조정하는 조성물의 용도
FI3220916T3 (fi) 2014-11-17 2023-06-19 Epizyme Inc Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla
JP6544507B2 (ja) 2015-02-09 2019-07-17 日本精機株式会社 ヘッドアップディスプレイ装置
WO2016201328A1 (en) 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
KR20170095656A (ko) 2016-02-15 2017-08-23 동부대우전자 주식회사 방열구조를 갖는 세탁기

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062720A2 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. K. KNUTSON ET AL,, SELECTIVE INHIBITION OF EZH2 BY EPZ-6438 LEADS TO POTENT ANTITUMOR ACTIVITY IN EZH2-MUTANT NON-HODGKIN LYMPHOMA, 1 April 2014 (2014-04-01) *

Also Published As

Publication number Publication date
EA038337B1 (ru) 2021-08-11
SG10201811128RA (en) 2019-01-30
KR102497728B1 (ko) 2023-02-09
KR20230031963A (ko) 2023-03-07
US20170216300A1 (en) 2017-08-03
EP3157527A4 (en) 2018-05-23
CA2952074C (en) 2022-08-30
ES2948442T3 (es) 2023-09-12
EP3157527A1 (en) 2017-04-26
US20240058348A1 (en) 2024-02-22
US20200323866A1 (en) 2020-10-15
CA2952074A1 (en) 2015-12-23
US20190175604A1 (en) 2019-06-13
HUE062158T2 (hu) 2023-10-28
EP4252851A2 (en) 2023-10-04
IL309539A (en) 2024-02-01
EP3157527B1 (en) 2023-05-24
MX2016016744A (es) 2017-11-30
LT3157527T (lt) 2023-07-25
SI3157527T1 (sl) 2023-09-29
CN106999498A (zh) 2017-08-01
BR112016029492A2 (pt) 2017-10-17
EP4252851A3 (en) 2023-11-22
AU2015277139A1 (en) 2016-12-22
US20200022987A1 (en) 2020-01-23
PL3157527T3 (pl) 2023-08-07
US10166238B2 (en) 2019-01-01
SG11201610273VA (en) 2017-01-27
CN106999498B (zh) 2021-06-08
JP2017518334A (ja) 2017-07-06
DK3157527T3 (da) 2023-07-03
CN113289022A (zh) 2021-08-24
WO2015195848A8 (en) 2016-07-07
PT3157527T (pt) 2023-06-30
EA201692285A8 (ru) 2018-01-31
IL285201B1 (en) 2024-01-01
NZ727108A (en) 2023-09-29
KR20170052558A (ko) 2017-05-12
AU2020244382A1 (en) 2020-10-29
JP6779793B2 (ja) 2020-11-04
EA201692285A1 (ru) 2017-06-30
AU2020244382B2 (en) 2022-08-04
MX383866B (es) 2025-03-14
IL285201A (en) 2021-08-31
WO2015195848A1 (en) 2015-12-23
MX2021007651A (es) 2021-08-11
FI3157527T3 (fi) 2023-07-25
AU2022263523A1 (en) 2022-12-08
IL249438A0 (en) 2017-02-28
US11642347B2 (en) 2023-05-09

Similar Documents

Publication Publication Date Title
AU2020244382B2 (en) Ezh2 inhibitors for treating lymphoma
US11951109B2 (en) EZH2 inhibitors for treating lymphoma
US20240180919A1 (en) Ezh2 inhibitors for treating cancer
AU2022256115A1 (en) Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type
EP4309738A2 (en) Method of treating medulloblastoma with an ezh2 inhibitor
CA2996412A1 (en) Method for treating cancer
HK40097684A (en) Ezh2 inhibitors for treating lymphoma
NZ727108B2 (en) Ezh2 inhibitors for treating lymphoma